Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Cahill, Kate ^a   Ussher, M ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

Body weight; Depression chemically induced ; Nausea chemically induced ; Piperidines adverse effects; *therapeutic use ; Pyrazoles adverse effects; *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; RIMONABANT; CANNABINOID 1 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANXIETY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; FATIGUE; HUMAN; MOOD DISORDER; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; ADULT; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG ANTAGONISM; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; SMOKING; SUICIDE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG THERAPY; META ANALYSIS; PREVENTION AND CONTROL; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION;

ADULT; BODY WEIGHT; DEPRESSION; HUMANS; NAUSEA; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, CANNABINOID, CB1; RECURRENCE; SMOKING; SMOKING CESSATION; SUICIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 36749075981     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005353.pub3     Document Type: Review

References (26)

1. STRATUS-EU 2006 {published and unpublished data} *Cinciripini PM, Aubin H-J, Dale LC, Niaura R, Anthenelli RM, Robinson J. Pooled analysis of three short-term, randomised, doubleblind, placebo-controlled trials with rimonabant 20mg/d in smoking cessation [PI-TS-01]. Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey. 2006.
2. Sanofi Aventis. Information Meeting. http://en.sanofi-aventis.com/Images/ en_050301_up_2004_Full_Year_Results_Analysts_Investors_meeting_in_Paris_ presentation_tcm24-3612.pdf (accessed 23rd November 2006) 2005.
3. STRATUS-US 2006 {published and unpublished data} Anthenelli RM, Depres J-P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUSUS Trial (smoking cessation in smokers motivated to quit) and the RIO-LIPIDS Trial (weight reducing and metabolic effects in overweight/obese patients with dyslipidemia. American College of Cardiology Annual Scientific Session. March 2004.
4. Boyd ST, Fremming BA. Rimonabant - a selective CB1 antagonist. Annals of Pharmacotherapy 2005;39:684-90.
5. *Cinciripini PM, Aubin H-J, Dale LC, Niaura R, Anthenelli RM, Robinson J. Pooled analysis of three short-term, randomised, doubleblind, placebo-controlled trials with rimonabant 20 mg/d in smoking cessation [PI-TS-01]. Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey. 2006.
6. STRATUS-WW 2005 {published and unpublished data} Niaura R. Long-term maintenance of abstinence from smoking with rimonabant: results from the STRATUS Worldwide trial. 1-year efficacy/safety results. American Thoracic Society Conference 2005.
7. Niaura R. Long-term maintenance of abstinence from smoking with rimonabant: reuslts from the STRATUS Worldwide trial. 6-month efficacy/safety results [POS1-054]. American Thoracic Society Conference. 2004.
8. Sanofi Aventis. Information Meeting. http://en.sanofi-aventis.com/Images/ en_050301_up_2004_Full_Year_Results_Analysts_Investors_meeting_in_Paris_ presentation_tcm24-3612.pdf (accessed 23rd November 2006) 2005.
9. STRATUS META 2006 Cinciripini PM, Aubin H-J, Dale LC, Niaura R, Anthenelli RM, Robinson J. Pooled analysis of three short-term, randomised, double-blind, placebo-controlled trials with rimonabant 20mg/d in smoking cessation [PI-TS-01]. Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey. 2006.
10. Sanofi Aventis. Comparison of efficacy and safety of rimonabant 20mg/day versus placebo in smoking cessation. http://clinicaltrials.gov/show/ NCT00464256 (accessed 17th October 2007) 2007.
11. ACC 2004 American College of Cardiology. Data shows new drug, rimonabant, helps smokers quit while limiting post cessation weight gain. www.eurekalert.org/pub_releases/2004-03/k-dsn030904.php (accessed September 15 2004).
12. Acomplia SPC 2006 Sanofi-Aventis. Acomplia 20mg Summary of Product Characteristics. http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp? documentid=18283 (accessed 18th April 2007) 2006.
13. Cleland 2004 Cleland JGF, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al.Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. European Journal of Heart Failure 2004;6:501-8.
14. Cochrane Handbook Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. http://www.cochrane.org/resources/handbook/hbook.htm (accessed 18th April 2007) 2006.
15. Curioni 2006 Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD006162. DOI:10.1002/14651858.CD006162.pub2.
16. FDA 2007 Food, Drug Administration. Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting on June 13, 2007. www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4306m1-final.pdf (accessed 6th August 2007) 2007.
17. Filozof 2004 Filozof C, Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. Obesity Review 2004;5:95-103.
18. Hughes 2003 Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5(1):13-25.
19. MHRA 2007 Medicines and Healthcare products Regulatory Agency. Risk of depression and suicidal behaviour with Acomplia (rimonabant). www.info.doh.gov.uk/doh/embroadcast.nsf/fd1653b6e6be59d180256b7900507749/83 vrrm.pdf (accessed 6th August 2007) 2007.
20. Mizoue 1998 Mizoue T, Ueda R, Tokui N, Hino Y, Yoshimura T. Body mass decrease after initial gain following smoking cessation. International Journal of Epidemiology 1998;27:984-8.
21. O'Hara 1998 O'Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R. Early and late weight gain following smoking cessation in the Lung Health Study. American Journal of Epidemiology 1998;148(9):821-30.
22. ONS 2002 Office for National Statistics. Smoking-related behaviour and attitudes. http://www.dh.gov.uk/assetRoot/04/06/81/56/04068156.pdf (accessed 11th April 2005).
23. Pomerleau 2000 Pomerleau CS, Pomerleau OF, Namenek RJ, Mehringer AM. Short-term weight gain in abstaining women smokers. Journal of Substance Abuse and Treatment 2000;18(4):339-42.
24. Sanofi 2003 Sanofi - Synthelabo. RIO and STRATUSD Clinical Studies Guide. Sanofi-Synthelabo, 2003.
25. Sanofi-Synth 2004 Sanofi-Synthelabo. Two pivotal studies indicate ACOMPLIA (rimonabant) offers a novel approach to cardiovascular risk management in overweight/obese people and smokers. http://es.sanofi-synthelabo.com/press/ ppc_23804.asp (accessed September 15 2004).
26. USPHS 1990 US Public Health Service. The health benefits of smoking cessation: A report of the Surgeon General. DHHS Publication No CDC 90-8416 1990; Vol. Washington DC.